Correlating physicochemical and biological properties to define critical quality attributes of a rAAV vaccine candidate.

Journal Information

Full Title: Mol Ther Methods Clin Dev

Abbreviation: Mol Ther Methods Clin Dev

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Medicine, Research & Experimental

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declaration of interests L.H.V. is an inventor on AAVCOVID and AAV vaccine patent applications and a founder and employee of ciendias bio, a vaccine biotechnology company. N.Z. is an inventor on AAVCOVID and AAV vaccine patent applications."

Evidence found in paper:

"This work was supported, in whole or in part, by the 10.13039/100000865Bill & Melinda Gates Foundation (INV ID-021035). Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. The authors would like to thank Saleh-Birdjandi Soraia from the Vaccine Analytics and Formulation Center at the University of Kansas for technical assistance."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025